Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colleen R Kelly

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Gastroenterology|October 4, 2024
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled TrialJessica R Allegretti, Colleen R Kelly, Thomas Louie, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Journal of Gastroenterology and Hepatology|March 27, 2025
Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi ConsensusFaming Zhang, Michael A Kamm, Xia Wu, et al.
Gut|February 13, 2020
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practiceCraig Haifer, Colleen R Kelly, Sudarshan Paramsothy, et al.
Inflammatory Bowel Diseases|November 6, 2020
Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile InfectionJessica R Allegretti, Colleen R Kelly, Ari Grinspan, et al.
The American Journal of Gastroenterology|June 4, 2014
Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patientsColleen R Kelly, Chioma Ihunnah, Monika Fischer, et al.
Gut|July 5, 2020
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemicGianluca Ianiro, Benjamin H Mullish, Colleen R Kelly, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
The Lancet. Infectious Diseases|April 16, 2023
Redefining Clostridioides difficile infection antibiotic response and clinical outcomesAnne J Gonzales-Luna, Andrew M Skinner, Carolyn D Alonso, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Gastroenterology|October 4, 2024
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled TrialJessica R Allegretti, Colleen R Kelly, Thomas Louie, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Journal of Gastroenterology and Hepatology|March 27, 2025
Preferred Reporting Items for Microbiotherapy (PRIM) Guidelines Across Medical Disciplines: An International Delphi ConsensusFaming Zhang, Michael A Kamm, Xia Wu, et al.
Gut|February 13, 2020
Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practiceCraig Haifer, Colleen R Kelly, Sudarshan Paramsothy, et al.
Inflammatory Bowel Diseases|November 6, 2020
Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile InfectionJessica R Allegretti, Colleen R Kelly, Ari Grinspan, et al.
The American Journal of Gastroenterology|June 4, 2014
Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patientsColleen R Kelly, Chioma Ihunnah, Monika Fischer, et al.
Gut|July 5, 2020
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemicGianluca Ianiro, Benjamin H Mullish, Colleen R Kelly, et al.
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
Infectious Diseases and Therapy|August 30, 2024
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
The Lancet. Infectious Diseases|April 16, 2023
Redefining Clostridioides difficile infection antibiotic response and clinical outcomesAnne J Gonzales-Luna, Andrew M Skinner, Carolyn D Alonso, et al.
Pageof 9